Recent approaches for enhancing the performance of dissolving microneedles in drug delivery applications
Dissolving microneedles (dMNs) are promising versatile drug delivery systems for the transdermal delivery of numerous drugs, enabling their use in a wide range of biomedical and pharmaceutical applications. Being made of water-soluble polymers, dMNs own several advantages, including fast dissolution and short application time which enhance patients’ compliance and minimize the damage to skin tissue. Moreover, they possess no biohazard risk as they leave no sharp waste behind.
For these reasons, the research on dMNs has increased dramatically in recent years. The formulation of successful dMNs requires a well-defined pre-set design, considering the goal and the payloads that will be used. Every aspect of formulation as patch design, needles geometry, polymer composition, method of formation and payloads, has a direct effect on the mechanical properties of the MNs, affecting their administration and efficacy. Thus, there is the need to understand how each factor affects the final formulation and how to optimize each MN. Taking this into consideration, this review serves as a guide for dMN formulation, discussing the different setbacks of each step and possible strategies to overcome them, improving their administration, and enhancing the loading of various molecules and their controlled release.
Table 1. Common polymers for the preparation of dissolving MNs.a
Polymer | Other compositions | Loaded bioactive agent | MNs application | Ref. |
---|---|---|---|---|
HA | Magnesium ascorbyl phosphate | [30] | ||
Methotrexate | Treatment of psoriasis | [31] | ||
MN-combined with bacterial nanocellulose as the back layer. | Rutin (model drug) | [32] | ||
Green tea extract | Wound healing | [33] | ||
Adenosine | Improve skin wrinkles, dermal density, and elasticity | [34] | ||
Sodium hyaluronate/ composite MNs chitosan | Ovalbumin (model antigen) | Intradermal immunization | [35] | |
MNs containing curcumin-loaded micelles | Curcumin | [36] | ||
Insulin | Diabetes | [37] | ||
MNs loaded with near-infrared responsive PEGylated gold nanorod | Doxorubicin | Human epidermoid cancer therapy | [38] | |
5-Aminolevulinic Acid | Photodynamic therapy of superficial tumors | [39] | ||
Sumatriptan Succinate | Migraine | [40] | ||
Gentamicin | Neonatal sepsis | [41] | ||
Alginate and hyaluronate | Insulin | Diabetes | [42] | |
Insulin | Diabetes | [43] | ||
IgG | Intradermal protein delivery | [44] | ||
PVP | Copolymer polyvinylpyrrolidone-co-methacrylic acid (PVP-MAA) | Allergen extracts | Skin allergy test | [45] |
mRNA | [46] | |||
Sinomenine hydrochloride | Anti-inflammatory | [47] | ||
Fluorescein sodium and fluorescein isothiocyanate–dextrans (model drugs) | Intraocular drug delivery | [16] | ||
Chitosan nanoparticles-loaded MNs | A model antigen, ovalbumin (OVA), and an adjuvant, CpG oligodeoxynucleotides (CpG). | [48] | ||
Cellulose derivatives | CMC | Ovalbumin | Vaccination | [49] |
CMC | Lidocaine | Anesthesia | [50] | |
CMC /powder-carrying MNs | Finasteride | Androgenetic alopecia | [51] | |
HPC | Cyclosporin A | [52] | ||
HPMC/PVP | Alpha-Arbutin | [53] | ||
Chitosan | Bovine serum albumin | Transdermal Delivery of Macromolecules | [54] | |
Vascular endothelial growth factor (VEGF) | Wound healing | [55] | ||
Chitosan MNs and a poly(l-lactide-co-d,l-lactide) (PLA) supporting array | Ovalbumin | Vaccination | [56] | |
Thiolated chitosan MNs | Tacrolimus | Immunosuppression | [57] | |
Meloxicam | Pain management in cattle | [58] | ||
Ovalbumin | Vaccination | [59] | ||
Luteinizing Hormone-releasing Hormone | Androgen Deprivation Therapy for lethal prostate cancer | [60] | ||
Alginate | Alginate and maltose | Insulin | Diabetes | [61] |
Bovine Serum Albumin | [62] | |||
Glucose-responsive gold nanocluster-loaded MNs | Insulin | Diabetes | [63] | |
silk fibroin | Insulin | Diabetes | [64] | |
Chemotherapeutic agents (thrombin and temozolomide) and targeted drug (bevacizumab) | [65] | |||
Influenza vaccine | Vaccination | [66] | ||
PVA | Doxorubicin | Cancer | [67] | |
PVA/PVP | Bovine serum albumin | Macromolecules delivery | [68] | |
PVA/PVP | Insulin | Diabetes | [69] | |
Cholecalciferol nanosuspension-loaded MNs (PVA or PVP) | Cholecalciferol | Loading of hydrophobic drug | [70] | |
PVA/maltose microneedle | Sinomenine hydrochloride | Rheumatoid arthritis | [71] |
Download the full study as PDF here: Recent approaches for enhancing the performance of dissolving microneedles in drug delivery applications
or read it here
Tomás Bauleth-Ramos, Nesma El-Sayed, Flavia Fontana, Maria Lobita, Mohammad-Ali Shahbazi, Hélder A. Santos, Recent approaches for enhancing the performance of dissolving microneedles in drug delivery applications, Materials Today, 2023, ISSN 1369-7021,
https://doi.org/10.1016/j.mattod.2022.12.007.
See also two other interesting artices on microneedles published lately:
- Dissolvable microneedles for transdermal drug delivery showing skin pentation and modified drug release
- Where Microneedle Meets Biomarkers: Futuristic Application for Diagnosing and Monitoring Localized External Organ Diseases